Segment reporting (Tables)

9 Months Ended

Sep. 30, 2026

Research and Development [Abstract]

Schedule of research and development expenses [Table Text Block]

	Three Months Ended September 30,		Nine Months Ended September 30,
	2026	2025	2026	2025
Research and development expenses:
SkinJect
Clinical, manufacturing and regulatory activities	464,223	1,114,470	2,475,511	3,568,401
Professional services and intellectual property	51,558	49,092	196,785	165,770
Teverelix
Clinical, manufacturing and regulatory activities	(1,389,137)	1,238	2,460,885	1,238
Professional services and intellectual property	37,358	-	115,699	-
CD228V
Professional services and intellectual property	80,649	-	80,649	-
Salaries and benefits	2,708,130	519,983	4,235,336	1,395,152
Total research and development expenses	1,952,780	1,684,783	9,564,865	5,130,561
Total general and administrative expenses	2,507,476	5,024,082	14,971,257	12,720,666
Total In-Process Research and Development (IPR&D) expenses	10,000,000	8,717,475	10,000,000	8,717,475
Total operating expenses	14,460,256	15,426,340	34,536,122	26,568,702
Other income (expense):
Interest income (expense), net	(712,652)	11,572	(1,236,441)	75,442
Loss on SEPA settlements	-	(157,721)	(127,083)	(157,721)
Change in fair value of debentures	-	(383,823)	-	(583,823)
Loss on extinguishment of debentures	-	(25,000)	-	(25,000)
Total other income (expense)	(712,652)	(554,972)	(1,363,524)	(691,102)
Net loss for the period	(15,172,908)	(15,981,312)	(35,899,646)	(27,259,804)